$395.52
-4.64[-1.16%]
At close: May 2
$395.52
0[0.00%]
PreMarket: 6:37PM EDT
Vertex Pharmaceuticals
(NASDAQ:VRTX)Latest News for Vertex Pharmaceuticals Stock (NASDAQ:VRTX)
Vertex Pharmaceuticals Stock (NASDAQ: VRTX)
Categories: All
Thursday, May 02, 2024
Friday, April 26, 2024
Thursday, April 25, 2024
Tuesday, April 23, 2024
Thursday, April 18, 2024
- Tesla To $123? Here Are 10 Top Analyst Forecasts For ThursdayAvi Kapoor - Apr 18, 2024, 8:46AM
- Vertex Pharmaceuticals Announced Advancements Across Its Suzetrigine Pain Program For Acute And Neuropathic PainBenzinga Newsdesk - Apr 18, 2024, 8:05AM
- Guggenheim Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $450Benzinga Newsdesk - Apr 18, 2024, 7:44AM
Tuesday, April 16, 2024
Monday, April 15, 2024
Friday, April 12, 2024
Thursday, April 11, 2024
- Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential ImpactVandana Singh - Apr 11, 2024, 2:47PM
- Stocks Bounce Back With Tech, Gold Gaining After Modest Producer Inflation Data: What's Driving Markets Thursday?Piero Cingari - Apr 11, 2024, 2:13PM
- Vertex Pharmaceuticals Moves Beyond $10B Cystic Fibrosis Franchise, Pays Around $5B For Kidney Disease Player Alpine ImmuneVandana Singh - Apr 11, 2024, 9:01AM
- HC Wainwright & Co. Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $462Benzinga Newsdesk - Apr 11, 2024, 7:51AM
- Wall Street Braces For Another Red Day Ahead Of More Inflation Data While Bitcoin Holds Above $70K: Analyst Sees Any Pullback As 'Phenomenal Buying Opportunity'Shanthi Rexaline - Apr 11, 2024, 7:27AM
- Evercore ISI Group Upgrades Vertex Pharmaceuticals to Outperform, Announces $438 Price TargetBenzinga Newsdesk - Apr 11, 2024, 6:50AM
Wednesday, April 10, 2024
Tuesday, April 09, 2024
Monday, April 01, 2024
- Reported Earlier, Vertex Advances Inaxaplin Into Phase 3 Portion Of Adaptive Phase 2/3 Clinical Trial For The Treatment Of APOL1-Mediated Kidney DiseaseBenzinga Newsdesk - Apr 1, 2024, 11:02AM
- Vertex Announces New Drug Submission For Exagamglogene Autotemcel Has Been Accepted For Priority Review By Health Canada For The Treatment Of Sickle Cell Disease And Transfusion-Dependent Beta ThalassemiaBenzinga Newsdesk - Apr 1, 2024, 11:01AM
Thursday, March 28, 2024
Monday, March 25, 2024
Friday, March 08, 2024
Friday, March 01, 2024
Thursday, February 29, 2024
Tuesday, February 27, 2024
Monday, February 26, 2024
Tuesday, February 20, 2024
Thursday, February 15, 2024
Tuesday, February 13, 2024
Wednesday, February 07, 2024
Tuesday, February 06, 2024
- Vertex's Next-Generation Cystic Fibrosis Program Shows Efficacy With Reduced Burden, Provides Growth Opportunity: Goldman SachsVandana Singh - Feb 6, 2024, 2:55PM
- Cantor Fitzgerald Reiterates Overweight on Vertex Pharmaceuticals, Maintains $440 Price TargetBenzinga Newsdesk - Feb 6, 2024, 2:37PM
- JP Morgan Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $450Benzinga Newsdesk - Feb 6, 2024, 2:23PM
- Vertex Pharmaceuticals shares are trading lower after the company reported Q4 financial results and issued guidance. Following earnings, Evercore ISI downgraded the stock from Outperform to In-Line.Benzinga Newsdesk - Feb 6, 2024, 2:01PM
- Wells Fargo Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $540Benzinga Newsdesk - Feb 6, 2024, 11:14AM
- RBC Capital Maintains Sector Perform on Vertex Pharmaceuticals, Raises Price Target to $420Benzinga Newsdesk - Feb 6, 2024, 11:03AM
- Barclays Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $472Benzinga Newsdesk - Feb 6, 2024, 10:51AM
- Vertex Pharmaceuticals' Triple Combo Treatment For Lung Disorder Meets Primary Goal In Adult And Pediatric PatientsVandana Singh - Feb 6, 2024, 9:57AM
- Evercore ISI Group Downgrades Vertex Pharmaceuticals to In-Line, Raises Price Target to $438Benzinga Newsdesk - Feb 6, 2024, 8:34AM
- Uber To Rally Around 15%? Here Are 10 Top Analyst Forecasts For TuesdayAvi Kapoor - Feb 6, 2024, 7:54AM
- HC Wainwright & Co. Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $457Benzinga Newsdesk - Feb 6, 2024, 6:46AM
Monday, February 05, 2024
- Vertex Pharmaceuticals Sees FY24 Revenue $10.55B-$10.75B Vs $10.61B Est.Benzinga Newsdesk - Feb 5, 2024, 4:08PM
- Vertex Pharmaceuticals Q4 EPS $4.20 Beats $4.10 Estimate, Sales $2.52B Beat $2.51B EstimateBenzinga Newsdesk - Feb 5, 2024, 4:07PM
- Vertex Announces Results From Pivotal Trials Of Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment For Cystic FibrosisBenzinga Newsdesk - Feb 5, 2024, 4:02PM